A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than did Thymoglobulin, ...
Aug 4, 2011
0
0
Iron overload is a common condition affecting millions of people worldwide. Excess iron in the body is toxic, and deposits can cause damage to the liver, heart and other organs. Current treatments, researchers say, are not ...
Nov 1, 2011
0
1
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director ...
Jun 7, 2022
0
3
The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration
Nov 16, 2011
0
0
Approved by the FDA earlier this year, the Alzheimer's therapy lecanemab is an antibody that reduces the buildup in the brain of a sticky peptide called amyloid-beta (Aβ), which is thought to be a main driver of the disease. ...
Sep 1, 2023
0
75
Americans' medicines are increasingly manufactured in developing countries, where oversight is lower than in the U.S., according to a new white paper by the Pew Health Group. The U.S. Food and Drug Administration (FDA) estimates ...
Jul 12, 2011
0
0
The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant ...
Jun 7, 2023
0
2
Pooled results from recent clinical trials indicate that an oral drug called roxadustat is an effective treatment for anemia in patients with chronic kidney disease. The results are published in an upcoming issue of CJASN.
Aug 6, 2021
0
3
A major challenge in human genetics is understanding which parts of the genome drive specific traits or contribute to disease risk. This challenge is even greater for genetic variants found in the 98% of the genome that does ...
May 4, 2023
0
33
(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).
Oct 26, 2012
0
0
